tiprankstipranks
Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aeterna Zentaris (AEZSResearch Report) and Atara Biotherapeutics (ATRAResearch Report) with bullish sentiments.

Aeterna Zentaris (AEZS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aeterna Zentaris, with a price target of $28.00. The company’s shares closed last Friday at $4.83, close to its 52-week low of $4.11.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -37.5% and a 18.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Timber Pharmaceuticals.

Currently, the analyst consensus on Aeterna Zentaris is a Moderate Buy with an average price target of $28.00.

See the top stocks recommended by analysts >>

Atara Biotherapeutics (ATRA)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Atara Biotherapeutics, with a price target of $29.00. The company’s shares closed last Friday at $3.22, close to its 52-week low of $3.20.

According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.8% and a 26.6% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics.

Atara Biotherapeutics has an analyst consensus of Hold, with a price target consensus of $20.50, representing a 471.0% upside. In a report issued on July 13, Roth Capital also maintained a Buy rating on the stock with a $24.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AEZS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More